These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31732691)
1. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach. Langille SE PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691 [TBL] [Abstract][Full Text] [Related]
2. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection. Melchore JA; Berdovich D PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593 [TBL] [Abstract][Full Text] [Related]
3. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885 [TBL] [Abstract][Full Text] [Related]
4. Achieving "Zero" Defects for Visible Particles in Injectables. Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141 [TBL] [Abstract][Full Text] [Related]
5. Particulate matter in injectable drug products. Langille SE PDA J Pharm Sci Technol; 2013; 67(3):186-200. PubMed ID: 23752747 [TBL] [Abstract][Full Text] [Related]
6. The need for new control strategies for particulate matter in parenterals. Poms J; Sacher S; Nixdorf M; Dekner M; Wallner-Mang S; Janssen I; Khinast JG; Schennach R Pharm Dev Technol; 2019 Jul; 24(6):739-750. PubMed ID: 30821571 [TBL] [Abstract][Full Text] [Related]
7. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations. Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504 [TBL] [Abstract][Full Text] [Related]
8. Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial. Timmons CL; Liu CY; Merkle S PDA J Pharm Sci Technol; 2017; 71(5):379-392. PubMed ID: 28512178 [TBL] [Abstract][Full Text] [Related]
9. Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry. Brown H; Mahler HC; Mellman J; Nieto A; Wagner D; Schaar M; Mathaes R; Kossinna J; Schmitting F; Dreher S; Roehl H; Hemminger M; Wuchner K PDA J Pharm Sci Technol; 2017; 71(2):147-162. PubMed ID: 27789803 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Particulate Matter in Liquid-Finished Dosage Forms. Duchek J; Havasi B PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612 [TBL] [Abstract][Full Text] [Related]
12. Particulate Study on NeoProfen, a Neonatal Injectable Product. Krishna A; Rice M; Kester T; Waters M; Wilson T PDA J Pharm Sci Technol; 2016; 70(1):76-92. PubMed ID: 26889056 [TBL] [Abstract][Full Text] [Related]
14. A strategy for reducing particulate contamination on opening glass ampoules and development of evaluation methods for its application. Lee KR; Chae YJ; Cho SE; Chung SJ Drug Dev Ind Pharm; 2011 Dec; 37(12):1394-401. PubMed ID: 21702739 [TBL] [Abstract][Full Text] [Related]